Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04078672
Other study ID # NOTAL-OCT V3.0
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2, 2019
Est. completion date March 26, 2023

Study information

Verified date April 2023
Source Notal Vision Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will include up to 250 AMD patients and up to 30 DR patients. In Tel Aviv medical center up to 100 AMD/ 20 DR patients will be recruited; In Assuta HaShalom up to 100 AMD/10 DR patients will be recruited; In Bnei Zion medical center up to 50 AMD patients will be recruited. 4.1 Study population 1. AMD patients - intermediate and advanced AMD (with active or non-active CNV) 2. DR patients - with and without edema 4.2 Inclusion criteria 1. Ability and agreement to give informed consent (IC) 2. Diagnosis of AMD or DR in SE by OCT 3. Ability to undergo OCT scans 4. VA of 20/400 (6/120) or better in study eye(s) 4.3 Exclusion criteria 1. Patient with dilated eye(s)


Description:

4.5.1 SCREENING VISIT: For patients eligible to participate in the study, the following procedure will be done in the screening visit: 1. Patient will sign the IC (Informed Consent) form 2. Test the eligible eye(s) of the patient will be tested 3. The following demographic and clinical data will be collected for each tested eye and will be registered in the CRF: 1. Patient's DOB and gender. 2. Patient's diagnosis in study eye(s), based on patient's medical record, including media opacity (e.g. cataract or corneal opacity, if exists). 3. Examination to check habitual correction, pinhole VA and refraction. 4.5.2 OCT Visit 1: may take place on the same day as screening visit. For each eligible eye, testing will include: d. Refraction by auto-refractometer e. Commercial OCT scanning: i. Scanning pattern: Macular cube of at least 6mm (20 degrees); At least 40 B-scans per cube f. NOTAL-OCT V3.0 scanning: i. Scanning pattern Macular cube of the central 10 degrees of the macula At least 40 B-scans per cube ii. The patients will undergo an interactive tutorial that will teach the patient to self-operate the NOTAL-OCT V3.0 device. The tutorial will be done only once, using the eye with the better VA. iii. To check repeatability, image capturing phase will include up to 8 testing sessions, each ~2 minutes long. iv. Patients will rest for 5 minutes between sessions. v. Total examination time with NOTAL-OCT V3.0 is expected to be less than an hour. vi. In case of patient's fatigue during the testing procedure, examination session will be terminated. vii. The study staff will administer the NOTAL-OCT V3.0 "patient-experience" questionnaire at the 1st OCT Visit. 4.5.3 OCT Visits 2-6: For each eligible eye, imaging will include: a. Commercial OCT scanning: i. Scanning pattern: Macular cube of at least 6mm (20 degrees); At least 40 B-scans per cube b. NOTAL-OCT V3.0 scanning: i. Scanning pattern Macular cube of the central 10 degrees of the macula At least 40 B-scans per cube ii. Image capturing phase that will include up to 8 testing sessions, each a~2 minutes long. iii. Patients will rest for 5 minutes between sessions. iv. Total examination time with the NOTAL-OCT V3.0 is expected to be less than an hour. v. In case of patient's fatigue during the testing procedure, examination will be terminated. c. VA of eye(s) participating in the study. d. Clinical diagnosis of eye(s) participating in the study.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date March 26, 2023
Est. primary completion date January 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Ability and agreement to give informed consent (IC) 2. Diagnosis of AMD or DR in SE by OCT 3. Ability to undergo OCT scans 4. VA of 20/400 (6/120) or better in study eye(s) Exclusion Criteria: - 1. Patient with dilated eye(s)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
NOTAL-OCT V3.0
AMD and DR patients

Locations

Country Name City State
Israel Assuta Hashalom Tel Aviv
Israel Tel Aviv Medical Center Tel Aviv

Sponsors (1)

Lead Sponsor Collaborator
Notal Vision Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the level of agreement between OCT images captured by NOTAL-OCT V3.0 and by a commercial OCT The measurement of fluid as identified by an eye-care professional, in the central 10 degrees of the macula of DR patients. Less then an hour
Secondary To evaluate the level of agreement between OCT images captured by NOTAL-OCT V3.0 and a by commercial OCT The measurement of fluid as identified by an eye-care professional, in the central 10 degrees of the macula of DR patients. Less then an hour
Secondary To evaluate repeatability To evaluate the repeatability of the detection of fluid in images captured by NOTAL-OCT V3.0 in the central 10 degrees of the macula of AMD and DR patients. Less then an hour
Secondary To evaluate the level of agreement between NOTAL-OCT V3.0 and a commercial OCT in the presence of fluid The measurement of fluid as identified by an eye-care professional, in the central 10 degrees of the macula. Less then an hour
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Recruiting NCT03893474 - Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners N/A
Completed NCT00971464 - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Phase 2
Terminated NCT00332657 - Anecortave Acetate Risk Reduction Trial (AART) Phase 3
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT01766596 - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) N/A
Completed NCT03322930 - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed NCT01778491 - AMD Phenotype and Genotype Study
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Active, not recruiting NCT03845582 - Phase 3 Study of ALK-001 in Geographic Atrophy Phase 3
Completed NCT03367767 - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Completed NCT03372746 - Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Terminated NCT00333216 - Anecortave Acetate Risk-Reduction Trial (AART) Phase 3
Completed NCT01570790 - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00346866 - Anecortave Acetate Versus Placebo in AMD Patients Following PDT Phase 2
Withdrawn NCT00726466 - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Phase 1
Completed NCT00306488 - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT01632527 - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A